The FDA has classified as Class I an ongoing recall by Fresenius Kabi USA of Tyenne (tocilizumab-aazg) injection, 400 mg/20 mL single-dose vials, after the firm's own internal investigation found glass particles in the product. The classification was posted on 2 September 2026 and the recall is listed as ongoing.
Class I is the most serious category the FDA uses, reserved for a defect with a reasonable probability of serious harm or death. Particulate matter in an intravenous product is not a theoretical concern: glass fragments can cause phlebitis, embolic and granulomatous complications, and an immediate infusion reaction. This is a manufacturing defect in specific lots, not a problem with tocilizumab or with biosimilars as a class, and it is not a signal about the drug's efficacy or its approved indications.
Practically, the action sits with whoever holds the stock. Infusion units using this product should identify affected lots against the FDA notice and quarantine them, and any patient who had an unexplained reaction to a recent infusion is worth a second look at the lot number. The 400 mg intravenous vial is the hospital infusion presentation, so the subcutaneous prefilled syringe used at home is a different product. In India, Tyenne is not the tocilizumab product in general use and CDSCO has not been reported as acting; if a patient raises it, the accurate answer is that this is an American recall of specific manufactured lots.
- Check infusion stock against the FDA lot numbers and quarantine anything affected
- Class I means a reasonable probability of serious harm — treat identification as urgent, not routine
- Review recent unexplained infusion reactions against the lot used
- This concerns the 400 mg/20 mL intravenous vial, not subcutaneous tocilizumab presentations
- Nothing here changes the case for tocilizumab itself or for biosimilars generally
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free